Supporting evidence for the association between atrophy and tau pathology in this subtype is not straightforward, owing to factors including the interval between assessments of these biomarkers,15 regional nonspecificity of atrophy, and disagreement of subtyping methods based on these biomarkers.39 Altogether, our study is useful in providing a direct link between antemortem atrophy and postmortem tau pathology, suggesting that hippocampal atrophy relative to neocortical atrophy can track postmortem NFT subtypes.16 The gene discussed is MAPT; the disease is Atrophy.